Evidence map›Paper›PMID 19276452›Full record

Trial reportJournal of the National Cancer Institute2009

Folic acid and risk of prostate cancer: results from a randomized clinical trial.

Jane C Figueiredo, Maria V Grau, Robert W Haile, Robert S Sandler, Robert W Summers, Robert S Bresalier, Carol A Burke, Gail E McKeown-Eyssen, John A Baron

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 9 pooled it
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 9 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. MTHFR C677T polymorphism contributes to the risk for gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010
    Pooled it
  10. Differential Biopsy Patterns Influence Associations between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jane C FigueiredoDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA. janefigu@usc.edu
Maria V Grau
Robert W Haile
Robert S Sandler
Robert W Summers
Robert S Bresalier
Carol A Burke
Gail E McKeown-Eyssen
John A Baron
Cleveland Clinic · USDartmouth College · USThe University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · USUniversity of Southern California · US

Funding

FOLATE, DNA METHYLATION AND CARCINOGENESIS IN THE BOWELR01CA059005 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARON, JOHN ANTHONY · 1993 to 2013
$17.3M
Folate, 1-Carbon Nutrients, Gene Variants &Colon CancerU54CA100971 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUNTER, DAVID JOHN · 2003 to 2008
$7.0M
NCI NIH HHS R01-CA-059005NCI NIH HHS U54-CA-100971
6 · The paper itself

Abstract

Data regarding the association between folate status and risk of prostate cancer are sparse and conflicting. We studied prostate cancer occurrence in the Aspirin/Folate Polyp Prevention Study, a placebo-controlled randomized trial of aspirin and folic acid supplementation for the chemoprevention of colorectal adenomas conducted between July 6, 1994, and December 31, 2006. Participants were followed for up to 10.8 (median = 7.0, interquartile range = 6.0-7.8) years and asked periodically to report all illnesses and hospitalizations. Aspirin alone had no statistically significant effect on prostate cancer incidence, but there were marked differences according to folic acid treatment. Among the 643 men who were randomly assigned to placebo or supplementation with folic acid, the estimated probability of being diagnosed with prostate cancer over a 10-year period was 9.7% (95% confidence interval [CI] = 6.5% to 14.5%) in the folic acid group and 3.3% (95% CI = 1.7% to 6.4%) in the placebo group (age-adjusted hazard ratio = 2.63, 95% CI = 1.23 to 5.65, Wald test P = .01). In contrast, baseline dietary folate intake and plasma folate in nonmultivitamin users were inversely associated with risk of prostate cancer, although these associations did not attain statistical significance in adjusted analyses. These findings highlight the potential complex role of folate in prostate cancer and the possibly different effects of folic acid-containing supplements vs natural sources of folate.

Indexed as

Dietary SupplementsAdenomaAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalAspirinColorectal NeoplasmsCyclooxygenase InhibitorsDouble-Blind MethodFolic AcidFollow-Up StudiesHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase InhibitorsFolic AcidVitamin B Complex

Identifiers

PMID19276452
PMCPMC2657096
OpenAlexW2169495321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.